tiprankstipranks
Pfizer (IT:1PFE)
:1PFE
Italy Market
1PFE
Pfizer
RESEARCH TOOLSreports

Pfizer (1PFE) Stock Forecast & Price Target

10 Followers
See the Price Targets and Ratings of:

1PFE Analyst Ratings

Moderate Buy
21Ratings
Moderate Buy
8 Buy
12 Hold
1 Sell
Based on 21 analysts giving stock ratings to
Pfizer
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1PFE Stock 12 Month Forecast

Average Price Target

€24.56
▲(1.91% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is €24.56 with a high forecast of €30.86 and a low forecast of €21.58. The average price target represents a 1.91% change from the last price of €24.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"€17","24":"€24","31":"€31","20.5":"€20.5","27.5":"€27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.855966212499997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.560384459558822,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.57759875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,20.5,24,27.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.705,22.408920477884614,23.11284095576923,23.816761433653845,24.52068191153846,25.224602389423076,25.92852286730769,26.632443345192307,27.336363823076923,28.040284300961538,28.744204778846154,29.448125256730766,30.15204573461538,{"y":30.855966212499997,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.705,21.9246449584276,22.1442899168552,22.363934875282805,22.583579833710406,22.803224792138007,23.022869750565608,23.242514708993212,23.462159667420813,23.681804625848415,23.901449584276016,24.12109454270362,24.34073950113122,{"y":24.560384459558822,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.705,21.695199903846152,21.685399807692306,21.67559971153846,21.665799615384614,21.655999519230768,21.646199423076922,21.636399326923076,21.62659923076923,21.616799134615384,21.606999038461538,21.597198942307692,21.587398846153846,{"y":21.57759875,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.867,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.759,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.463,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.89,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.837,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.181,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.706,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.479,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.034,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.591,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.608,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.705,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€30.86Average Price Target€24.56Lowest Price Target€21.58
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on IT:1PFE
Louise Chen
Scotiabank
Scotiabank
€25.89
Buy
7.44%
Upside
Reiterated
08/24/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein Analyst forecast on IT:1PFE
Courtney Breen
Bernstein
Bernstein
€25.89→€25.03
Hold
3.86%
Upside
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Innoviva (NASDAQ: INVA) and Pfizer (NYSE: PFE)
BMO Capital Analyst forecast on IT:1PFE
Evan Seigerman
BMO Capital
BMO Capital
€25.89
Buy
7.44%
Upside
Reiterated
08/17/26
Pfizer (PFE) Gets a Buy from BMO Capital
Barclays Analyst forecast on IT:1PFE
Emily Field
Barclays
Barclays
€21.58
Sell
-10.47%
Downside
Reiterated
08/13/26
Barclays Sticks to Their Sell Rating for Pfizer (PFE)
TD Cowen Analyst forecast on IT:1PFE
Steve Scala
TD Cowen
TD Cowen
―
Buy
―
Initiated
08/11/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), Pfizer (NYSE: PFE) and Sana Biotechnology (NASDAQ: SANA)
CMB International Securities Analyst forecast on IT:1PFE
Jill Wu
CMB International Securities
CMB International Securities
€30.61→€30.86
Buy
28.03%
Upside
Reiterated
08/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NASDAQ: NRXP), Novo Nordisk (NYSE: NVO) and Pfizer (NYSE: PFE)
Guggenheim Analyst forecast on IT:1PFE
Vamil Divan
Guggenheim
Guggenheim
€30.21→€26.76
Buy
11.02%
Upside
Reiterated
08/06/26
Pfizer price target lowered to $31 from $35 at GuggenheimPfizer price target lowered to $31 from $35 at Guggenheim
DZ BANK AG Analyst forecast on IT:1PFE
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Qiagen (NYSE: QGEN), COMPASS Pathways (NASDAQ: CMPS) and Pfizer (NYSE: PFE)
Citi Analyst forecast on IT:1PFE
Geoff Meacham
Citi
Citi
―
Hold
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Allogene Therapeutics (NASDAQ: ALLO)
Jefferies Analyst forecast on IT:1PFE
Akash Tewari
Jefferies
Jefferies
€29.35
Buy
21.77%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)
Wells Fargo Analyst forecast on IT:1PFE
Mohit Bansal
Wells Fargo
Wells Fargo
€24.17
Hold
0.28%
Upside
Reiterated
08/05/26
Wells Fargo Keeps Their Hold Rating on Pfizer (PFE)
Argus Research Analyst forecast on IT:1PFE
David Toung
Argus Research
Argus Research
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sight Sciences (NASDAQ: SGHT)
Berenberg Bank Analyst forecast on IT:1PFE
Kerry Holford
Berenberg Bank
Berenberg Bank
€21.58
Hold
-10.47%
Downside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Lipocine (NASDAQ: LPCN) and High Tide (NASDAQ: HITI)
Bank of America Securities Analyst forecast on IT:1PFE
Jason Gerberry
Bank of America Securities
Bank of America Securities
€22.44→€23.3
Hold
-3.30%
Downside
Reiterated
08/04/26
Pfizer: Mixed Q2 Update and Limited Long‑Term Visibility Keep Hold Rating as Price Target Nudged Up to $27
RBC Capital Analyst forecast on IT:1PFE
Trung Huynh
RBC Capital
RBC Capital
€21.58
Hold
-10.47%
Downside
Reiterated
08/04/26
RBC Capital Remains a Hold on Pfizer (PFE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on IT:1PFE
Louise Chen
Scotiabank
Scotiabank
€25.89
Buy
7.44%
Upside
Reiterated
08/24/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein Analyst forecast on IT:1PFE
Courtney Breen
Bernstein
Bernstein
€25.89→€25.03
Hold
3.86%
Upside
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Innoviva (NASDAQ: INVA) and Pfizer (NYSE: PFE)
BMO Capital Analyst forecast on IT:1PFE
Evan Seigerman
BMO Capital
BMO Capital
€25.89
Buy
7.44%
Upside
Reiterated
08/17/26
Pfizer (PFE) Gets a Buy from BMO Capital
Barclays Analyst forecast on IT:1PFE
Emily Field
Barclays
Barclays
€21.58
Sell
-10.47%
Downside
Reiterated
08/13/26
Barclays Sticks to Their Sell Rating for Pfizer (PFE)
TD Cowen Analyst forecast on IT:1PFE
Steve Scala
TD Cowen
TD Cowen
―
Buy
―
Initiated
08/11/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), Pfizer (NYSE: PFE) and Sana Biotechnology (NASDAQ: SANA)
CMB International Securities Analyst forecast on IT:1PFE
Jill Wu
CMB International Securities
CMB International Securities
€30.61→€30.86
Buy
28.03%
Upside
Reiterated
08/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NASDAQ: NRXP), Novo Nordisk (NYSE: NVO) and Pfizer (NYSE: PFE)
Guggenheim Analyst forecast on IT:1PFE
Vamil Divan
Guggenheim
Guggenheim
€30.21→€26.76
Buy
11.02%
Upside
Reiterated
08/06/26
Pfizer price target lowered to $31 from $35 at GuggenheimPfizer price target lowered to $31 from $35 at Guggenheim
DZ BANK AG Analyst forecast on IT:1PFE
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Qiagen (NYSE: QGEN), COMPASS Pathways (NASDAQ: CMPS) and Pfizer (NYSE: PFE)
Citi Analyst forecast on IT:1PFE
Geoff Meacham
Citi
Citi
―
Hold
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Allogene Therapeutics (NASDAQ: ALLO)
Jefferies Analyst forecast on IT:1PFE
Akash Tewari
Jefferies
Jefferies
€29.35
Buy
21.77%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)
Wells Fargo Analyst forecast on IT:1PFE
Mohit Bansal
Wells Fargo
Wells Fargo
€24.17
Hold
0.28%
Upside
Reiterated
08/05/26
Wells Fargo Keeps Their Hold Rating on Pfizer (PFE)
Argus Research Analyst forecast on IT:1PFE
David Toung
Argus Research
Argus Research
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sight Sciences (NASDAQ: SGHT)
Berenberg Bank Analyst forecast on IT:1PFE
Kerry Holford
Berenberg Bank
Berenberg Bank
€21.58
Hold
-10.47%
Downside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Lipocine (NASDAQ: LPCN) and High Tide (NASDAQ: HITI)
Bank of America Securities Analyst forecast on IT:1PFE
Jason Gerberry
Bank of America Securities
Bank of America Securities
€22.44→€23.3
Hold
-3.30%
Downside
Reiterated
08/04/26
Pfizer: Mixed Q2 Update and Limited Long‑Term Visibility Keep Hold Rating as Price Target Nudged Up to $27
RBC Capital Analyst forecast on IT:1PFE
Trung Huynh
RBC Capital
RBC Capital
€21.58
Hold
-10.47%
Downside
Reiterated
08/04/26
RBC Capital Remains a Hold on Pfizer (PFE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

3 Months
Vamil DivanGuggenheim
Success Rate
25/34 ratings generated profit
74%
Average Return
+3.72%
Copying Vamil Divan's trades and holding each position for 3 Months would result in 73.53% of your transactions generating a profit, with an average return of +3.72% per trade.
1 Year
Vamil DivanGuggenheim
Success Rate
30/34 ratings generated profit
88%
Average Return
+9.34%
Copying Vamil Divan's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +9.34% per trade.
2 Years
Steve ScalaTD Cowen
Success Rate
21/23 ratings generated profit
91%
Average Return
+25.45%
Copying Steve Scala's trades and holding each position for 2 Years would result in 91.30% of your transactions generating a profit, with an average return of +25.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1PFE Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
18
21
21
20
21
Hold
32
36
45
40
36
Sell
5
6
8
5
3
Strong Sell
0
0
0
0
0
total
55
63
74
65
60
In the current month, 1PFE has received 21 Buy Ratings, 36 Hold Ratings, and 3 Sell Ratings. 1PFE average Analyst price target in the past 3 months is 24.56.
Each month's total comprises the sum of three months' worth of ratings.

1PFE Financial Forecast

1PFE Earnings Forecast

Next quarter’s earnings estimate for 1PFE is €0.66 with a range of €0.51 to €0.81. The previous quarter’s EPS was €0.66. 1PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1PFE is €0.66 with a range of €0.51 to €0.81. The previous quarter’s EPS was €0.66. 1PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.

1PFE Sales Forecast

Next quarter’s sales forecast for 1PFE is €13.75B with a range of €12.93B to €14.55B. The previous quarter’s sales results were €12.98B. 1PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.
Next quarter’s sales forecast for 1PFE is €13.75B with a range of €12.93B to €14.55B. The previous quarter’s sales results were €12.98B. 1PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.

1PFE Stock Forecast FAQ

What is IT:1PFE’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer’s 12-month average price target is 24.56.
    What is IT:1PFE’s upside potential, based on the analysts’ average price target?
    Pfizer has 1.91% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Pfizer a Buy, Sell or Hold?
          Pfizer has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 12 hold ratings and 1 sell ratings.
            What is Pfizer’s share price target?
            The average share price target for Pfizer is 24.56. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €30.86 ,and the lowest forecast is €21.58. The average share price target represents 1.91% Increase from the current price of €24.1.
              What do analysts say about Pfizer?
              Pfizer’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of Pfizer?
                To buy shares of IT:1PFE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.